Comparing LENZ Therapeutics (LENZ) and Its Peers

LENZ Therapeutics (NASDAQ:LENZ) is one of 290 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare LENZ Therapeutics to similar companies based on the strength of its analyst recommendations, dividends, profitability, risk, institutional ownership, earnings and valuation.

Volatility & Risk

LENZ Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, LENZ Therapeutics’ peers have a beta of 1.05, indicating that their average share price is 5% more volatile than the S&P 500.

Profitability

This table compares LENZ Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-33.12%	-27.96%
LENZ Therapeutics Competitors	-4,487.51%	-224.30%	-45.25%

Insider and Institutional Ownership

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 38.4% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 16.0% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares LENZ Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
LENZ Therapeutics	N/A	-$124.65 million	-1.04
LENZ Therapeutics Competitors	$543.17 million	-$37.24 million	8.72

LENZ Therapeutics’ peers have higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for LENZ Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0	0	5	0	3.00
LENZ Therapeutics Competitors	1438	4561	11943	208	2.60

LENZ Therapeutics currently has a consensus price target of $31.33, indicating a potential upside of 93.65%. As a group, “Biological products, except diagnostic” companies have a potential upside of 66.61%. Given LENZ Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe LENZ Therapeutics is more favorable than its peers.

Summary

LENZ Therapeutics beats its peers on 8 of the 13 factors compared.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.